
Kosuke Iwasaki
FIAJ, MAAA, MBA
Principal
Tokyo, JP
Kosuke Iwasaki joined Milliman’s Tokyo office in 1999 and moved to New York in 2000. As a consulting actuary in healthcare and life insurance, he has contributed to or managed projects with life/health insurance companies, pharmaceutical companies, medical device companies, disease management companies, managed care organizations, and research institutes.
After 13 years in New York, he returned to Milliman’s Tokyo office in July of 2013 to establish the firm’s healthcare and data analytics practice in Japan.
Experience
- Health technology assessment (HTA) including cost-effectiveness, cost-utilization, and cost-benefit analysis for pharmaceutical companies and medical device companies
- Economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
- Economic value of bariatric surgery
- Economic value of disease management programs and screening
- Analysis on adverse drug events for hospitals
- Value-based design of health insurance, including the cost-sharing structure of diabetes drugs and chemotherapy for cancer patients
- Development of a predictive model for a disease management company in Japan
- Development of a predictive model for long-term care cost
- Development of budget impact models (BIMs) for drugs for diabetes and hepatitis C patients
- Development of benchmarks on outcomes for hospitals
- Stochastic modeling, including:
- Generalized linear model (GLM)
- Survival model
- Hierarchal Bayesian model
- Bayesian network model
- Development of healthcare reform models for accountable care organizations (ACOs)
- Development of health insurance products, disability income products, long-term care products, and critical illness products for life and health insurance companies
- Pricing and profit testing of insurance policies
- Due diligence in M&A of life/health insurance companies
He is a member of the Institute of Actuaries of Japan’s Health Insurance Committee.
Professional Designations
- Fellow, Institute of Actuaries of Japan
- Member, American Academy of Actuaries
Education
- BS, Mathematics, Tokyo University
- MBA, Columbia University
Publications
Read their latest work
Article
日本における骨折による介護負担とその推移 ―官庁統計を用いた分析
25 February 2019 - by Kosuke Iwasaki
日本における骨折による介護費用を、官庁統計として公開されているデータを用いて推算しました。介護費用は経年的に増加し、平成28年には約2兆円と推算され、家族の介護負担が最も高い割合を示しました。
Article
健康保険給付データの分析に基づく日本における多発性硬化症の罹患率、治療、医療費(英語版のみ)
26 September 2017 - by Kosuke Iwasaki
本稿は、日本における多発性硬化症の現在の治療状況および医療費を検討するため、健康保険給付データを分析したものです。
Article
日本のリアルワールドデータを用いたARB型降圧薬を使用した初期治療後の二次・三次降圧治療の分析(英語版のみ)
01 August 2016 - by Kosuke Iwasaki, Yujiro Otsuka
本調査は、日本の高血圧患者においてARB型降圧薬を使用した初期治療後に処方された降圧剤の併用状況を分析したものです。
Article
日本のレセプトデータ分析に基づく多発性硬化症の治療および医療費の現状(英語版のみ)
04 April 2016 - by Kosuke Iwasaki, Yujiro Otsuka
本研究では、レセプトデータベースを利用することで、日本における多発性硬化症の患者集団、治療、費用に関する最新の情報をほぼリアルタイムで提供しています。
Article
An actuarial study of hemophilia: Implications for commercial and Medicaid managed care plans
05 March 2014 - by Kosuke Iwasaki, Bruce S. Pyenson
This paper discusses the financial risks associated with hemophilia and outlines the issues for regulators, insurers, and provider organizations financially managing the care for this and other rare and expensive medical conditions.
Article
米国医療制度改革とC型肝炎(英語版のみ)
19 December 2013 - by Tyler Engel, Kate Fitch, Kosuke Iwasaki, Bruce S. Pyenson
C型肝炎は、米国ではベビーブーマー世代(1950年代生まれ)にのみ高い有病率を示す病気です。
Article
Comparing episode of cancer care costs in different settings: An actuarial analysis of patients receiving chemotherapy
09 October 2013 - by Kate Fitch, Kosuke Iwasaki, Bruce S. Pyenson
Chemotherapy treatment in hospital outpatient settings vs. in physicians offices in on the rise and increasing costs.
Article
The incidence rate and economic burden of community-acquired pneumonia in a working-age population
01 September 2013 - by Jonah Broulette, Kosuke Iwasaki, Bruce S. Pyenson
What is the economic impact of community-acquired pneumonia (CAP) in the employed population?
Article
Major depressive disorder: An actuarial commercial claim data analysis
31 July 2013 - by Kate Fitch, Kosuke Iwasaki
Evaluating antidepressant formulary access and benefit design should help support effective antidepressant treatments in patients with major depressive disorder.
Article
民間被保険者人口における大鬱病障害患者の薬剤抵抗性の数理分析 (英語版のみ)
03 January 2013 - by Kate Fitch, Kosuke Iwasaki, Bruce S. Pyenson
大鬱病障害を有する患者の薬剤抵抗性はどのように費用に影響するのか?